The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Abstract Background Small cell lung cancer (SCLC) is a deadly neuroendocrine tumor with limited therapeutic options. Recent data suggest that histone deacetylases (HDACs) and the phosphatidylinositol 3-kinase (PI3K) pathway play essential roles in SCLC cell proliferation and survival. Methods The in...

Full description

Bibliographic Details
Main Authors: Liying Ma, Xing Bian, Wenchu Lin
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
SCLC
PI3K
HDAC
CUDC-907
PARP1
Olaparib
Online Access:http://link.springer.com/article/10.1186/s13046-020-01728-2

Internet

http://link.springer.com/article/10.1186/s13046-020-01728-2

Similar Items